Figure 1From: Second-line Treatment of Stage III/IV Non-Small-Cell Lung Cancer (NSCLC) with pemetrexed in routine clinical practice: Evaluation of performance status and health-related quality of life Shift table presenting the number of patients by baseline KI and KI after second treatment cycle with pemetrexed. KI = Karnofsky IndexBack to article page